BOSTON — Despite a signal of potential superiority of the Cre8 EVO drug-eluting stent (DES) over the Resolute Onyx DES at 1 year post-percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM), the 2-year results failed to show superiority of the new DES.